Author: Lundstrom, Kenneth
Title: Alphavirus-Based Vaccines Document date: 2014_6_16
ID: 07iwwsfz_28
Snippet: A number of vaccine development studies have been conducted using mainly the three most commonly applied alphavirus vectors, SFV, SIN and VEE. To demonstrate the variety of approaches available, replicon particles, naked RNA and layered DNA vectors have been employed. Each approach has commonly generated responses detected by cellular or humoral responses. In the case of vaccine development against lethal viruses (Table 1) , non-viral infectious .....
Document: A number of vaccine development studies have been conducted using mainly the three most commonly applied alphavirus vectors, SFV, SIN and VEE. To demonstrate the variety of approaches available, replicon particles, naked RNA and layered DNA vectors have been employed. Each approach has commonly generated responses detected by cellular or humoral responses. In the case of vaccine development against lethal viruses (Table 1) , non-viral infectious targets ( Table 2 ) and tumors ( Table 3) immunization has provided long-term protection against challenges with the disease-causing agents. Moreover, due to the pathogenicity of several alphaviruses, they are themselves credible targets for vaccine development. Therefore, a number of studies, particularly for VEE and CHIK (Table 4) , have provided protection against challenges with virulent alphavirus strains.
Search related documents:
Co phrase search for related documents- alphavirus vector and disease cause: 1
- alphavirus vector and dna vector: 1
- alphavirus vector and layered dna vector: 1
- alphavirus vector and lethal virus: 1
- alphavirus vector and long term: 1, 2, 3
- alphavirus vector and long term protection: 1, 2
- alphavirus vector and vaccine development: 1
- available approach and disease cause: 1, 2, 3, 4
- available approach and humoral cellular response: 1
- available approach and lethal virus: 1
- available approach and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- available approach and long term protection: 1
- available approach and study number: 1
- available approach and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8
- disease cause and dna vector: 1
- disease cause and humoral cellular response: 1, 2
- disease cause and infectious target: 1
- disease cause and lethal virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date